b4gat1 Antibody

What is B4GAT1 and why is it important in glycobiology research?

B4GAT1 (beta-1,4-glucuronyltransferase 1) is a glycosyltransferase enzyme with a molecular weight of approximately 47.1 kDa (55 kDa in SDS-PAGE) that consists of 415 amino acid residues in humans. It localizes to the Golgi apparatus and belongs to the Glycosyltransferase 49 protein family . The protein was previously mischaracterized as B3GNT1 (a β1,3-N-acetylglucosaminyltransferase) but has been correctly identified as a β1,4-glucuronyltransferase that transfers glucuronic acid (GlcA) residues onto xylose (Xyl) acceptors .

B4GAT1 is critically important in glycobiology research because it forms a glucuronyl-β1,4-xylosyl disaccharide that serves as an acceptor primer for LARGE, which subsequently synthesizes the functional glycan on alpha-dystroglycan (α-DG) . Mutations in B4GAT1 have been associated with muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies (MDDGA13), making it an important target for both basic glycobiology and clinical research .

What cell types and tissues express B4GAT1?

B4GAT1 expression has been confirmed in multiple experimental cell lines including IMR-32 human neuroblastoma cells and HEK293T human embryonic kidney cells, as demonstrated by Western blot analysis . The protein plays an important role in axon guidance, suggesting significant expression in neural tissues .

From an evolutionary perspective, B4GAT1 is highly conserved, with orthologs reported in multiple species including mouse, rat, bovine, frog, zebrafish, and chimpanzee . This conservation underscores its fundamental biological importance across vertebrates. For research purposes, this means that antibodies with cross-reactivity to these species can be valuable tools for comparative studies.

When designing experiments to study B4GAT1 expression, researchers should consider targeting tissues associated with muscular dystrophy and neurological development, as these are the systems most affected by B4GAT1 dysfunction.

What are the most effective applications for B4GAT1 antibodies?

B4GAT1 antibodies have demonstrated effectiveness in several key applications:

• Western Blot (WB): This is the most widely used application, with optimal antibody concentration typically around 2 μg/mL . B4GAT1 typically appears at approximately 55 kDa on reducing SDS-PAGE gels .

• Enzyme-Linked Immunosorbent Assay (ELISA): Useful for quantitative detection of B4GAT1 in solution-phase samples .

• Immunohistochemistry (IHC): Enables visualization of B4GAT1 localization within tissues and cells, particularly for studying its Golgi localization .

When selecting a B4GAT1 antibody for specific applications, researchers should verify the validated applications for that particular antibody clone or lot, as performance can vary significantly between manufacturers and even between antibody lots.

How do I distinguish between B4GAT1 and its previously assigned identity (B3GNT1)?

Distinguishing between B4GAT1 and its previously mischaracterized identity as B3GNT1 requires understanding both its enzymatic activity and molecular characteristics:

• Enzymatic activity assessment: B4GAT1 shows β1,4-glucuronyltransferase activity, transferring GlcA onto Xyl acceptors with a β1,4 linkage. In contrast, the originally proposed B3GNT1 activity (β1,3-N-acetylglucosaminyltransferase) transfers N-acetylglucosamine with a β1,3 linkage. Researchers have been unable to validate any N-acetylglucosaminyltransferase activity for this protein .

• Protein domains: B4GAT1 shares 44% similarity with the LARGE GlcA-T domain (CAZy: GT49), supporting its identity as a glucuronyltransferase .

• Functional assays: When selecting antibodies, ensure they target epitopes relevant to the glucuronyltransferase function rather than the incorrectly attributed N-acetylglucosaminyltransferase function.

Understanding this distinction is crucial for experiment design and data interpretation, particularly when referencing older literature that may use the B3GNT1 nomenclature.

What is the appropriate sample preparation for optimal B4GAT1 detection?

For optimal B4GAT1 detection in experimental samples:

• Cell lysis conditions: Since B4GAT1 is a Golgi-localized membrane protein, use lysis buffers containing non-ionic detergents (e.g., 1% Triton X-100 or 0.5% NP-40) to effectively solubilize membrane components while preserving protein structure.

• Reducing conditions: Western blot detection of B4GAT1 is typically performed under reducing conditions , suggesting the presence of disulfide bonds that may affect antibody recognition.

• Post-translational modifications: B4GAT1 undergoes glycosylation , which can affect its apparent molecular weight and antibody recognition. For applications requiring native protein detection, avoid deglycosylation steps. For size analysis, consider parallel samples with and without deglycosylation treatment.

• Buffer compatibility: When detecting B4GAT1 by Western blot, Immunoblot Buffer Group 8 has been reported as effective . Verify buffer compatibility with your specific antibody based on manufacturer recommendations.

How do mutations in B4GAT1 affect its detection by antibodies?

Various disease-causing B4GAT1 mutations have significant consequences for antibody detection:

• Patient-derived mutation (N390D): This mutation, identified in a patient with Walker-Warburg syndrome, appears to maintain normal Golgi localization, suggesting that antibodies targeting Golgi-localized B4GAT1 may still detect this variant .

• DXD motif mutation (D227N/D229N): Mutations in the glycosyltransferase signature DXD motif affect subcellular localization of B4GAT1, potentially altering detection in immunofluorescence assays .

• Mouse model mutation (M155T): This mutation, identified in B4gat1-deficient mice with axon guidance defects, also affects subcellular localization .

Researchers studying disease-associated mutations should carefully select antibodies that recognize epitopes distant from the mutation site. Additionally, antibodies recognizing different domains of B4GAT1 can be used in parallel to confirm expression and localization patterns of mutant proteins.

What controls should be included when validating B4GAT1 antibody specificity?

Robust validation of B4GAT1 antibody specificity requires multiple control strategies:

• Positive controls:

  • IMR-32 human neuroblastoma and HEK293T human embryonic kidney cell lines have confirmed B4GAT1 expression

  • Mouse embryonic fibroblasts (MEFs) from wild-type mice express endogenous B4GAT1

• Negative controls:

  • B4gat1-deficient MEFs (LacZ/LacZ B4gat1 knockout) show minimal to no B4GAT1 expression

  • Hypomorphic MEFs (LacZ/M155T B4gat1) show significantly reduced (<3%) B4GAT1 activity compared to wild-type cells

  • Peptide competition assays can confirm antibody specificity

• Specificity verification:

  • Western blot should show a primary band at approximately 55 kDa

  • Immunoprecipitation followed by mass spectrometry can confirm the identity of the immunoprecipitated protein

How can B4GAT1 enzymatic activity be measured to complement antibody detection?

B4GAT1 enzymatic activity assessment provides crucial functional data to complement antibody-based detection:

• HPLC-based assay: A high-performance liquid chromatography approach has been developed for B4GAT1 activity. This assay uses:

  • Recombinant B4GAT1 (transmembrane domain deleted, B4GAT1dTM) or cell lysates containing endogenous B4GAT1

  • UDP-GlcA as sugar donor

  • Fluorescently labeled β-xyloside (4-methylumbelliferyl-β-D-xyloside, Xyl-β-MU) as acceptor

• Acceptor specificity testing:

  • B4GAT1 shows >10-fold higher preference for β-linked Xyl acceptors compared to α-linked Xyl

  • No activity is observed with UDP-GlcNAc and Gal-β1,4-GlcNAc-β-MU acceptor

• Radiolabeling assay:

  • [14C]-labeled UDP-Xyl and/or UDP-GlcA can be used to measure glycosyl-transfer to appropriate acceptor glycoproteins

This enzymatic activity assay can serve as a diagnostic tool for measuring endogenous B4GAT1 activity in patient cells and tissues, providing quantitative data on residual enzyme function in disease states.

What is the relationship between B4GAT1 and LARGE in glycosylation research?

Understanding the functional relationship between B4GAT1 and LARGE is critical for glycosylation studies:

• Sequential enzymatic action: B4GAT1 synthesizes the glucuronyl-β1,4-xylosyl disaccharide that serves as the acceptor primer for LARGE to initiate formation of the terminal heteropolysaccharide involved in ligand binding .

• Independent enzymatic activities: Research has demonstrated that the enzymatic activities of B4GAT1 and LARGE operate independently, with mutations in one gene product not affecting the activity of the other .

• Complementary experimental approaches:

  • B4GAT1 assays using recombinant LARGE (LARGEdTM) and acceptor protein DGFc340 from Large-deficient MEFs can help delineate the specific roles of each enzyme

  • Parallel immunodetection of both proteins can provide insights into their co-localization and potential physical interactions

• Disease relevance: Both proteins are implicated in muscular dystrophy-dystroglycanopathy, making them important dual targets for therapeutic research .

How do B4GAT1 expression patterns differ across development and disease states?

Understanding B4GAT1 expression across developmental stages and in disease contexts:

• Developmental expression:

  • B4GAT1-deficient (B4gat1-/-) mice die perinatally, indicating essential roles during embryonic development

  • The protein plays crucial roles in axon guidance during neural development

• Disease-specific alterations:

  • In muscular dystrophy-dystroglycanopathy, even hypomorphic B4GAT1 activity (~3% of wild-type) can produce functional but reduced amounts of α-DG capable of binding laminin

  • Mutations affect both protein localization and enzymatic activity, with varying severity depending on the specific mutation

• Experimental considerations:

  • When studying developmental contexts, embryonic tissue sampling timepoints should be carefully selected based on B4GAT1's critical developmental windows

  • Disease model studies should incorporate quantitative antibody-based detection methods coupled with enzymatic activity assays to correlate B4GAT1 levels with disease severity

What are the optimal Western blot conditions for B4GAT1 detection?

For optimal Western blot detection of B4GAT1:

• Sample preparation:

  • Use appropriate lysis buffers containing non-ionic detergents for membrane protein extraction

  • Process samples under reducing conditions with DTT or β-mercaptoethanol

• Antibody concentration:

  • 2 μg/mL has been established as an effective concentration for B4GAT1 detection in cell line lysates

  • Titration may be necessary for different tissue samples or antibody lots

• Detection parameters:

  • Expected molecular weight: approximately 55 kDa on SDS-PAGE

  • Membrane type: PVDF membrane has been successfully used

  • Secondary antibody: HRP-conjugated anti-mouse IgG has been effective when using mouse monoclonal primary antibodies

• Buffer system:

  • Immunoblot Buffer Group 8 has been reported as compatible with B4GAT1 detection

  • Ensure all buffers are freshly prepared and at the correct pH

How can I distinguish between endogenous B4GAT1 and recombinant tagged versions?

Differentiating between endogenous and recombinant B4GAT1:

• Size-based discrimination:

  • Endogenous B4GAT1: approximately 55 kDa

  • Recombinant versions with tags (e.g., Myc-tag, His-tag) will show increased molecular weight corresponding to the tag size

  • Transmembrane domain deletion constructs (B4GAT1dTM) will show decreased molecular weight

• Tag-specific antibodies:

  • Use tag-specific antibodies (anti-Myc, anti-His) to selectively detect recombinant tagged proteins

  • In co-expression experiments, perform parallel blots with tag-specific and B4GAT1-specific antibodies

• Experimental controls:

  • Include untransfected cells as negative controls for tag detection

  • Consider using B4GAT1-deficient cell lines (when available) as negative controls for endogenous protein

• Immunoprecipitation strategy:

  • Perform immunoprecipitation with tag-specific antibodies followed by Western blot with B4GAT1-specific antibodies to confirm identity

What are the common pitfalls in immunostaining for B4GAT1 localization?

When performing immunostaining to visualize B4GAT1 localization:

• Golgi localization challenges:

  • B4GAT1 localizes to the trans-Golgi near the TGN (trans-Golgi network)

  • Co-staining with established Golgi markers (e.g., Giantin) is essential for confirmation

  • Ensure proper fixation to preserve Golgi structure (4% paraformaldehyde often preferred over methanol)

• Mutation effects on localization:

  • Some B4GAT1 mutations (D227N/D229N and M155T) affect subcellular localization

  • Different antibodies may have variable ability to detect mislocalized protein

• Fixation and permeabilization:

  • Membrane proteins require careful optimization of permeabilization conditions

  • Excessive permeabilization can disrupt Golgi structure and cause artificial staining patterns

  • Consider mild detergents (0.1% Triton X-100 or 0.1% saponin) for permeabilization

• Antibody penetration:

  • Ensure sufficient incubation time for antibody penetration into Golgi structures

  • Consider using smaller antibody formats (e.g., Fab fragments) for improved access to sterically hindered epitopes

How can I design experiments to study B4GAT1 interactions with glycosylation substrates?

For investigating B4GAT1 interactions with glycosylation substrates:

• In vitro glycosyltransferase assays:

  • Utilize recombinant soluble B4GAT1 (B4GAT1dTM) expressed in HEK293T cells

  • Test various donor substrates (UDP-GlcA, UDP-GlcNAc) and acceptor substrates (Xyl-β-MU, Gal-β1,4-GlcNAc-β-MU)

  • Analyze reaction products using HPLC with fluorescence detection

• Acceptor specificity analysis:

  • Compare activity with β-linked versus α-linked acceptors

  • Quantify relative preferences using enzyme kinetics (Km, Vmax determinations)

  • B4GAT1 shows >10-fold higher preference for β-linked Xyl acceptors

• Structural analyses:

  • Consider nuclear magnetic resonance (NMR) for detailed structure analysis of glycan products

  • Couple enzymatic assays with mass spectrometry to confirm product identities

• Mutation impact studies:

  • Compare wild-type B4GAT1 with disease-associated mutants

  • Correlate enzyme activity levels with structural alterations in active site residues

What complementary techniques should be used alongside B4GAT1 antibody detection?

To gain comprehensive insights into B4GAT1 biology:

• Enzymatic activity assays:

  • HPLC-based assays using fluorescent acceptors (Xyl-β-MU)

  • Radiolabeling assays with [14C]-labeled UDP-GlcA

  • These provide functional validation complementing antibody detection

• Glycan analysis techniques:

  • Mass spectrometry to analyze glycan structures

  • Lectin staining to detect specific glycan signatures

  • These methods help connect B4GAT1 expression with functional glycosylation outcomes

• Gene expression analysis:

  • RT-qPCR for B4GAT1 mRNA levels

  • RNA-seq for transcriptome-wide effects of B4GAT1 manipulation

  • These approaches help establish transcriptional regulation patterns

• Functional readouts:

  • Laminin binding assays for α-DG glycosylation status

  • Cell adhesion and migration assays for functional consequences

  • These assays connect molecular findings to cellular phenotypes

What emerging technologies might enhance B4GAT1 antibody-based research?

The future of B4GAT1 research will likely be enhanced by:

• Proximity labeling techniques (BioID, APEX) to identify B4GAT1 interaction partners in the Golgi

• CRISPR-Cas9 genome editing to generate reporter cell lines with endogenously tagged B4GAT1

• Super-resolution microscopy for detailed visualization of B4GAT1 within Golgi subdomains

• Single-cell glycoproteomics to assess B4GAT1-dependent glycosylation heterogeneity within tissues